Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Shares Outstanding (Diluted Average): 2020-2025

Historic Shares Outstanding (Diluted Average) for Seres Therapeutics (MCRB) over the last 4 years, with Mar 2025 value amounting to $8.7 million.

  • Seres Therapeutics' Shares Outstanding (Diluted Average) rose 19.30% to $8.7 million in Q1 2025 from the same period last year, while for Mar 2025 it was $8.7 million, marking a year-over-year increase of 19.30%. This contributed to the annual value of $155.4 million for FY2024, which is 21.40% up from last year.
  • Per Seres Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $8.7 million for Q1 2025, which was down 94.39% from $155.4 million recorded in Q4 2024.
  • Seres Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $155.4 million for Q4 2024, and its period low was $7.3 million during Q1 2024.
  • In the last 3 years, Seres Therapeutics' Shares Outstanding (Diluted Average) had a median value of $128.1 million in 2023 and averaged $104.5 million.
  • As far as peak fluctuations go, Seres Therapeutics' Shares Outstanding (Diluted Average) surged by 40.75% in 2023, and later slumped by 94.20% in 2024.
  • Quarterly analysis of 5 years shows Seres Therapeutics' Shares Outstanding (Diluted Average) stood at $91.7 million in 2021, then increased by 17.86% to $108.1 million in 2022, then climbed by 18.44% to $128.0 million in 2023, then climbed by 21.40% to $155.4 million in 2024, then increased by 19.30% to $8.7 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $8.7 million for Q1 2025, versus $155.4 million for Q4 2024 and $152.6 million for Q3 2024.